Hyperion DeFi Inc

Hyperion DeFi Inc has a market capitalization of $51.43 million and a price-to-book ratio of 28.29, indicating a significant premium to its book value. The company's liquidity position is characterized by a current ratio of 0.88, suggesting potential short-term liquidity constraints. The debt-to-equity ratio of 8.2 highlights a high leverage position, with long-term debt amounting to $14.91 million against total equity of $1.82 million.

Profitability metrics for Hyperion DeFi Inc are negative, with a return on equity of -6.01% and a return on assets of -0.42%. These figures are well below the typical performance of the pharmaceutical industry, which generally maintains positive returns on equity and assets. The company reported a net loss of $10.92 million and an operating loss of $10.27 million, indicating significant operational challenges.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data suggests a need for further transparency.

Hyperion DeFi Inc's growth trajectory is currently negative, with a substantial decline in operating and net income. The company's free cash flow is negative at -$10.70 million, and capital expenditures are minimal at -$114,110. Analysts have assigned a mean price target of $6.28, with a median of $6.28, indicating a potential upside from the current market price of $3.62. However, the absence of strong buy recommendations and the presence of two buy ratings suggest cautious optimism.

The risk assessment for Hyperion DeFi Inc identifies medium liquidity risk and low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations without external financing. The low dilution risk is attributed to the absence of significant dilutive events in the recent financial data.

Recent events and filings for Hyperion DeFi Inc do not include any material disclosures or significant corporate actions. The company's financial statements and analyst estimates provide the primary basis for the current assessment. There are no notable transcripts or filings that indicate strategic shifts or operational changes in the near term.

Hyperion DeFi Inc. (HYPD.O) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of June 30, 2024, investor ID 466 acquired 124,799 shares, representing a portfolio weight of approximately 0.000168% and a value of $0.074 million. This activity was detected on June 20, 2026, and stands as the primary signal of interest in the absence of other cross-source signals or prior historical data for comparison. The significance of this holder change is contextualized by the company’s current structural profile. Hyperion DeFi Inc. currently reports zero officers and zero analyst coverage, indicating a lack of public-facing executive leadership or professional market analysis at this time. Furthermore, the company holds no index memberships, suggesting it is not yet integrated into major market benchmarks. Despite the absence of analyst ratings or index inclusion, the company maintains a base of nine top holders. The entry of investor ID 466 adds to this existing group, though the specific identity of the investor is not disclosed in the available data. The transaction size remains relatively small in absolute terms, with a value under $100,000. This initial analysis establishes a baseline for Hyperion DeFi Inc., as there is no prior basis for computing deltas in material changes. Future assessments will rely on comparing subsequent holder movements or corporate developments against this starting point. No additional financial, ESG, or estimate data is currently available to further characterize the company’s performance or outlook.

Analysts project 152.7% upside to a mean price target of $6.95, signaling strong institutional confidence in future valuation recovery.

Revenue surged 1,318.7% year-over-year to $813,460 in FY2026, indicating a significant acceleration in top-line business activity.

The company maintains a healthy current ratio of 2.68, suggesting sufficient short-term liquidity to cover immediate operational obligations.

Dilution risk is assessed as low, implying that existing shareholders face minimal immediate threat from equity issuance.

Gross profit turned positive at $510,170 in FY2026, marking a potential inflection point in direct cost management.

The company carries a high credit risk flag, indicating significant concerns regarding its ability to meet debt obligations.

Net margin of -2,188.8% places the firm in the bottom quartile of the pharmaceutical cohort, reflecting extreme unprofitability.

Return on equity stands at -6.01%, ranking in the bottom quartile and demonstrating poor capital efficiency for shareholders.

Debt-to-equity ratio of 8.2 is in the bottom quartile, indicating excessive leverage relative to peer pharmaceutical companies.

Revenue $496.2k, +1 666,6% YoY; Operating income −104,4% YoY.

• ▍Revenue $496.2k, +1 666,6% YoY
• ▍Operating income −104,4% YoY
• ▍Net income −99,3% YoY
• ▍Net margin -8013.5%

Revenue $302.5k, +18 458,9% YoY; Operating income +191,0% YoY.

• ▍Revenue $302.5k, +18 458,9% YoY
• ▍Operating income +191,0% YoY
• ▍Net income +184,0% YoY
• ▍Free cash flow −686,5% YoY
• ▍Net margin 2190.2%

Operating income +28,5% YoY; Net income +21,4% YoY.

• ▍Operating income +28,5% YoY
• ▍Net income +21,4% YoY
• ▍Free cash flow +18,7% YoY

Revenue $14.7k, +195,0% YoY; Operating income +71,3% YoY.

• ▍Revenue $14.7k, +195,0% YoY
• ▍Operating income +71,3% YoY
• ▍Net income +68,1% YoY
• ▍Free cash flow +67,5% YoY
• ▍Net margin -23665.3%

Revenue $28.1k; Operating income -$19.5M.

• ▍Revenue $28.1k
• ▍Operating income -$19.5M
• ▍Net margin -71038.7%

Revenue $1.6k; Operating income -$7.3M.

• ▍Revenue $1.6k
• ▍Operating income -$7.3M
• ▍Net margin -483917.2%

Revenue $22.6k; Operating income -$11.7M.

• ▍Revenue $22.6k
• ▍Operating income -$11.7M
• ▍Net margin -48845.3%

Revenue $5.0k; Operating income -$10.3M.

• ▍Revenue $5.0k
• ▍Operating income -$10.3M
• ▍Net margin -218879.8%

Revenue $813.5k, +1 318,7% YoY; Operating income +8,9% YoY.

• ▍Revenue $813.5k, +1 318,7% YoY
• ▍Operating income +8,9% YoY
• ▍Net income +9,0% YoY
• ▍Free cash flow −145,3% YoY
• ▍Net margin -5570.6%

Revenue $57.3k, +1 412,9% YoY; Operating income −91,8% YoY.

• ▍Revenue $57.3k, +1 412,9% YoY
• ▍Operating income −91,8% YoY
• ▍Net income −82,8% YoY
• ▍Free cash flow −66,6% YoY
• ▍Net margin -86882.5%

Revenue $3.8k; Operating income +5,6% YoY.

• ▍Revenue $3.8k
• ▍Operating income +5,6% YoY
• ▍Net income +2,7% YoY
• ▍Free cash flow −2,6% YoY
• ▍Net margin -719290.2%

Revenue $0.00, −100,0% YoY; Operating income −116,3% YoY.

• ▍Revenue $0.00, −100,0% YoY
• ▍Operating income −116,3% YoY
• ▍Net income −119,2% YoY
• ▍Free cash flow −101,6% YoY